VU 0255035

VU0255035 is a highly selective and competitive M1 mAChR antagonist. VU0255035 blocks M1 mAChR signals to reduce epileptic seizures and regulate neuronal membrane potential. VU0255035 can be used in research related to central nervous system diseases, such as epilepsy, Parkinson's disease, and dystonia[1][2][3].

Product Specifications

CAS Number

[1135243-19-4]

Product Name Alternative

VU 255035

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/vu-0255035.html

Purity

99.76

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(C1=CC=CC2=NSN=C21)(NCCC(N3CCN(C4=CC=NC=C4)CC3)=O)=O

Molecular Formula

C18H20N6O3S2

Molecular Weight

432.52

Precautions

H302, H315, H319, H335

References & Citations

[1]Sheffler DJ, et al. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol. 2009 Aug;76 (2) :356-68.|[2]Grafe EL, et al. Effects of prenatal ethanol exposure on choline-induced long-term depression in the hippocampus. J Neurophysiol. 2021 Nov 1;126 (5) :1622-1634.|[3]Kurowski P, et al. Muscarinic receptor control of pyramidal neuron membrane potential in the medial prefrontal cortex (mPFC) in rats. Neuroscience. 2015 Sep 10;303:474-88.